1.Gastrointestinal Motility Modulating Drugs.
Journal of the Korean Medical Association 2009;52(9):920-927
Gastrointestinal motility modulating drugs include all compounds which have pharmacological activity of modulating (stimulating or inhibiting) gastrointestinal motility. They are mainly used for the treatment of functional gastrointestinal diseases. Gastrointestinal motility modulating drugs include 5HT receptor agonists, antagonists, and antidopaminergic agents. Many new gastrointestinal motility modulating drugs are currently under investigation. The aims of this article are to review the mechanism of action, efficacy and side effects of the gastrointestinal motility modulating drugs.
Gastrointestinal Diseases
;
Gastrointestinal Motility
3.Radiation Exposure and Functional Gastrointestinal Disease.
Intestinal Research 2014;12(4):335-336
No abstract available.
Gastrointestinal Diseases*
5.Pharmacological Therapy of Functional Gastrointestinal Disorders.
Journal of the Korean Medical Association 2000;43(11):1131-1141
No abstract available.
Gastrointestinal Diseases*
6.A clincal study of upper gastrointestinal diseases diagnosed bygastrofiberscope.
Byung Joo KANG ; Seung Hoi PARK ; Min Ok CHANG ; Kyeong Soo CHEON ; Hei Soon PARK ; Young Sik KIM
Journal of the Korean Academy of Family Medicine 1991;12(8):10-18
No abstract available.
Gastrointestinal Diseases*
7.Understanding the Rome IV: Functional Constipation and Anorectal Disorders.
Korean Journal of Medicine 2017;92(4):372-381
We used mainly the Rome diagnostic criteria to diagnose functional gastrointestinal disease (FGID). The revised Rome IV was announced in 2016. Rome IV is the recognition that a considerable overlap exists between some of the FGIDs and that they may exist as part of a spectrum, rather than discrete disorders. Based on this concept, the Rome IV criteria for functional constipation and anorectal disorders are newly revised. We review the background and content of the Rome IV diagnostic criteria and introduce the multidimensional clinical profile using clinical cases. These revised criteria will be helpful for adequately diagnosing and managing these patients in actual clinical practice.
Constipation*
;
Gastrointestinal Diseases
;
Humans
8.Understanding the Rome IV: Background to the Rome IV Revision.
Han Seung RYU ; Suck Chei CHOI
Korean Journal of Medicine 2017;92(4):349-353
Functional gastrointestinal disorders (FGIDs) are common and may be serious. As such disorders are identified principally on the basis of their symptoms, symptom-based classifications assume great importance. The Rome diagnostic criteria for FGIDs are widely used in both research and practice. Over time, the criteria have been revised as new data accumulate; the Rome IV criteria were recently released. The changes from the Rome III criteria principally reflect the data of literature reports and committee recommendations based on all available evidence. Here, we offer a historical perspective and discuss the Rome IV changes.
Classification
;
Gastrointestinal Diseases
9.Neuropeptide S Receptor Induces Neuropeptide Expression and Associates With Intermediate Phenotypes of Functional Gastrointestinal Disorders (Gastroenterology 2010;138:98-107).
Journal of Neurogastroenterology and Motility 2010;16(2):218-220
No abstract available.
Gastrointestinal Diseases
;
Neuropeptides
;
Phenotype
10.The Effect of Stress and Depression on Gastrointestinal Diseases: Author's Reply.
Journal of Neurogastroenterology and Motility 2015;21(3):453-453
No abstract available.
Depression*
;
Gastrointestinal Diseases*
Result Analysis
Print
Save
E-mail